Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

Clinical trial NCT07151326 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07151326
Sponsor: National Health Research Institutes, Taiwan
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)

Start date: 2025-09-01
Primary completion: 2028-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.